RT Journal Article
SR Electronic
T1 Laboratory findings associated with severe illness and mortality among hospitalized individuals with coronavirus disease 2019 in Eastern Massachusetts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20090555
DO 10.1101/2020.05.04.20090555
A1 Victor M. Castro
A1 Thomas H. McCoy
A1 Roy H. Perlis
YR 2020
UL http://medrxiv.org/content/early/2020/08/28/2020.05.04.20090555.abstract
AB Importance The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented stress on health systems across the world, and reliable estimates of risk for adverse hospital outcomes are needed.Objective To quantify admission laboratory and comorbidity features associated with critical illness and mortality risk across 6 Eastern Massachusetts hospitals.Design Retrospective cohort study using hospital course, prior diagnoses, and laboratory values.Setting Emergency department and inpatient settings from 2 academic medical centers and 4 community hospitals.Participants All individuals with hospital admission and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR testing across these 6 hospitals through June 5, 2020.Exposure Coronavirus 2 (SARS-CoV-2).Main Outcome Measures Severe illness defined by ICU admission, mechanical ventilation, or death.Results Among 2,511 hospitalized individuals who tested positive for SARS-CoV-2 (of whom 50.9% were male, 53.9% white, and 27.0% Hispanic, with mean age 62.6 years), 215 (8.6%) were admitted to the ICU, 164 (6.5%) required mechanical ventilation, and 292 (11.6%) died. L1-regression models developed in 3 of these hospitals yielded area under ROC curve (AUC) of 0.807 for severe illness and 0.847 for mortality in the 3 held-out hospitals. In total, 212/292 (78%) of the deaths occurred in the highest-risk mortality quintile.Conclusions and Relevance In this cohort, specific admission laboratory studies in concert with sociodemographic features and prior diagnosis facilitated risk stratification among individuals hospitalized for COVID-19.Funding 1R56MH115187-01Trial Registration NoneQuestion How well can sociodemographic features, laboratory values, and comorbidities of individuals hospitalized with coronavirus disease 2019 (COVID-19) in Eastern Massachusetts through June 5, 2020 predict severe illness course?Findings In this cohort study of 2,511 hospitalized individuals positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR who were admitted to one of six hospitals, 215 (8.6%) were admitted to the ICU, 164 (6.5%) required mechanical ventilation, and 292 (11.6%) died. In a risk prediction model, 212 (78%) deaths occurred in the top mortality-risk quintile.Meaning Simple prediction models may assist in risk stratification among hospitalized COVID-19 patients.Competing Interest StatementNo funding was received for this study. Dr. Perlis has received consulting fees from Burrage Capital, Genomind, RID Ventures, and Takeda. He holds equity in Outermost Therapeutics and Psy Therapeutics. Dr. McCoy has received research funding from the Stanley Center at the Broad Institute, the Brain and Behavior Research Foundation, National Institute of Mental Health, National Human Genome Research Institute Home, and Telefonica Alfa. Mr. Castro reports no conflict of interest. Dr. Perlis had no role in the editorial review or decision to accept the manuscript for publication. Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Partners HealthCare Human Research Committee. No participant contact was required in this study which relied on secondary use of data produced by routine clinical care, allowing waiver of requirement for informed consent as detailed by 45 CFR 46.116. STROBE reporting guidelines for cohort studies were applied.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIRB approval does not allow for sharing of data outside of health system